Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Zydus Cadila
SK set for Korean trial with vaccine, as Biological E begins human trials of Baylor vaccine. Meanwhile, DongWha gets a Phase II nod for potential drug, and Celltrion progesses with Phase II regdanvimab trial.
As Bharat Biotech prepares its COVID-19 vaccine for a launch in the quarter ending next 30 September and claims at least 60% efficacy, questions arise over why trials were not temporarily halted following a serious adverse event during Phase I and why this wasn’t disclosed to participants in subsequent studies.
With seven COVID-19 treatment/prophylactic candidates lined up, India's Zydus Cadila is unleashing all it can to combat the disease. Meanwhile, the firm has also offered an update on the state of its injectables and transdermals business in the US, which is contingent on resolving deficiencies at its Moraiya plant.
In a broad-ranging interview with Scrip, the ex-CEO of India's Hilleman Laboratories compares the profiles of leading COVID-19 vaccines and urges caution around how far some of the new data now rolling out should be interpreted. The executive also outlines solutions to tackle logistics issues and "vaccine hesitancy" in countries like India.
- Generic Drugs
- OTC, Consumer
- Other Names / Subsidiaries
- Cadila Healthcare
- Zydus Pharmaceuticals USA
- German Remedies
- Zynesher Pharmaceuticals USA LLC
- Nesher Pharmaceuticals Inc
- Quimica e Farmaceutica Nikkho do Brasil Ltda
- Bremer Pharma GmbH
- Nippon Universal Pharmaceuticals
- Zydus Discovery DMCC
- Zydus Urosciences
- Sentynl Therapeutics, Inc.